Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Roanoke Memorial Hospital — Roanoke, Virginia
- Valley Health / Winchester Medical Center — Winchester, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Virginia: - Investigative Site US076 — Charlottesville, Virginia
- Investigative Site US057 — Fairfax, Virginia
- Investigative Site US065 — Fairfax, Virginia
- Investigative Site US064 — Salem, Virginia
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Virginia: - Exelixis Clinical Site #3 — Charlottesville, Virginia
- Exelixis Clinical Site #13 — Fairfax, Virginia
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Virginia: - University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Virginia: - UVA Emily Couric Cancer Center — Charlottesville, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Virginia: - VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Virginia: - Ohio State University-Telemedicine — Norfolk, Virginia
- Ohio State University-Telemedicine — Richmond, Virginia
- Ohio State University Telemedicine — Roanoke, Virginia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Virginia: - Blue Ridge Cancer Care — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Virginia: - Next Oncology Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…
Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Virginia: - NEXT, Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Sponsor: CivaTech Oncology
NCT ID: NCT02843945
Sites in Virginia: - Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or ch…
Sponsor: Phanes Therapeutics
NCT ID: NCT05431270
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07223047
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia